Applied dna sharpens strategic focus on synthetic dna manufacturing for biotherapeutics applications, consolidates operations behind linearx

- conducts 27% workforce reduction, ceases operations at applied dna clinical labs, positions linearx for growth - stony brook, ny / access newswire / june 30, 2025 / applied dna sciences, inc. (nasdaq:apdn), a leader in pcr-based dna technologies, announced a strategic restructuring and realignment of resources to focus exclusively on its synthetic dna manufacturing business, linearx. as part of actions undertaken, the company implemented a workforce reduction of approximately 27% of headcount and has ceased operations at applied dna clinical labs (adcl), a business that provides molecular and genetic testing services, effective june 27, 2025.
DNA Ratings Summary
DNA Quant Ranking